

Relationships Between Eosinophilic Inflammation, Tissue Remodeling, and Fibrosis in Eosinophilic Esophagitis

Seema S. Aceves, MD, PhD^{a,b,c}, Steven J. Ackerman, PhD^{d,e,*}

KEYWORDS

- Eosinophilic esophagitis • Eosinophils • Inflammation
- Remodeling • Fibrosis • Angiogenesis
- Transforming growth factor- β

Eosinophilic esophagitis (EE) is a disease of increasing prevalence and detection.^{1–4} Its pathogenesis relies in part on an allergic immune reaction that can involve both IgE and T-cell mediated hypersensitivity to inhaled aeroallergens and ingested food allergens. The clinical manifestations of EE include vomiting, abdominal pain, regurgitation, heartburn, and failure to thrive, especially in young children. In adolescents and

This work was supported by grants from the National Institutes of Health, R21AI079925 (SJA); an American Gastroenterological Association (AGA) Translational Research Award (SJA); an American Partnership for Eosinophilic Diseases (APFED) HOPE Research Award (SSA); an American Academy of Allergy, Asthma, Immunology Junior Women in Allergy grant (SSA); and a gift from the Campaign Urging Research on Eosinophilic Diseases (CURED) (SJA).

^a Division of Allergy and Immunology, Rady Children's Hospital, 3020 Children's Way, MC 5114, San Diego, CA 92123–6791, USA

^b Department of Pediatrics, Division of Allergy and Immunology, 9500 Gilman Drive, MC-0635, University of California, La Jolla, CA 92093, USA

^c Department of Medicine, Division of Allergy and Immunology, 9500 Gilman Drive, MC-0635, University of California, La Jolla, CA 92093, USA

^d Department of Biochemistry and Molecular Genetics (M/C 669), 900 South Ashland Avenue, Room 2074, Molecular Biology Research Building, The University of Illinois at Chicago College of Medicine, Chicago, IL 60607–7170, USA

^e Department of Medicine, 900 South Ashland Avenue, University of Illinois at Chicago, Chicago, IL 60607–7170, USA

* Corresponding author. Department of Biochemistry and Molecular Genetics (M/C 669), 900 South Ashland Avenue, Room 2074, Molecular Biology Research Building, The University of Illinois at Chicago College of Medicine, Chicago, IL 60607.

E-mail address: 7170.sackerma@uic.edu (S.J. Ackerman).

Immunol Allergy Clin N Am 29 (2009) 197–211

doi:10.1016/j.iac.2008.10.003

immunology.theclinics.com

0889-8561/08/\$ – see front matter © 2009 Elsevier Inc. All rights reserved.

adults, the symptoms can progress to odynophagia and dysphagia that can be associated with the clinical complications of food impactions with or without concurrent esophageal strictures.⁵⁻⁷ EE seems to be a chronic disease with persistent dysphagia when left untreated in adults.⁸ In children, the disease remits with therapies, including systemic or topical esophageal corticosteroids, and elimination or elemental diets, but recurs in most patients when the therapeutic intervention is removed.⁹

The histopathologic changes that occur in EE traverse the depths of the esophageal wall.^{10,11} The mucosa becomes infiltrated with eosinophils, mast cells, and T cells, and active proliferation of the epithelium leads to the histologic finding of basal zone hyperplasia.^{12,13} The submucosal lamina propria also becomes infiltrated by inflammatory cells and demonstrates increased collagen deposition that provides an extracellular matrix for the capture of cells and their cytokine, interleukin (IL), and chemokine¹⁴⁻¹⁷ products. The muscularis mucosa and the circular and longitudinal muscle layers have reported abnormalities with hypertrophy and dysfunction.¹⁰ In combination, the multiple facets of esophageal remodeling and subepithelial fibrosis that occur during the instigation and propagation of EE could explain many of the clinical symptoms. This article reviews the known aspects of esophageal remodeling, the basic molecular mechanisms used by eosinophils to promote tissue remodeling and fibrosis, and the clinical correlates of esophageal remodeling in EE.

Based on the paradigms of other eosinophil-mediated diseases, the role of tissue remodeling in the pathogenesis and clinical manifestations of EE is beginning to be investigated (**Fig. 1**). Tissue remodeling in response to Th2 and eosinophil-associated diseases was first characterized in the hypereosinophilic syndrome and asthma.¹⁸⁻²¹ In hypereosinophilic syndrome, eosinophil activation and degranulation causes target organ fibrosis. Significant patient mortality and morbidity is related to the development of endomyocardial fibrosis and subsequent cardiac failure associated with eosinophilic infiltration.^{21,22} Another Th2- and eosinophil-associated disease, asthma, is characterized by tissue remodeling consisting of airway epithelial cell transformation to mucous production, smooth muscle hyperplasia and hypertrophy, subepithelial fibrosis, and angiogenesis.¹⁹ These histologic and structural changes cause clinical disease manifestations of bronchial hyperreactivity, airway edema, and mucous plugging with subsequent airway lumen narrowing. In a subset of patients, these airways obstruction becomes irreversible. Although the role of the eosinophil in hypereosinophilic syndrome is clear, its role in asthma is beginning to be resolved.^{18,23}

Murine models of asthma have demonstrated a significant contribution of the eosinophil to disease pathogenesis. Double transgenic mice with airway eotaxin-2 and systemic IL-5 have severe asthma and collagen deposition that is significantly diminished if the animals lack eosinophils.^{20,24} The best human correlate to absent eosinophils is treatment with anti-IL-5 antibodies. Through the reduction in IL-5, the major eosinophilopoietic stimulus is lost. As compared with control patients, asthmatics treated with a humanized, monoclonal anti-IL-5 antibody demonstrate decreased levels of extracellular matrix proteins, such as lumican, tenascin, and procollagen III.²⁵ Studies on the role of tissue remodeling in eosinophilic gastrointestinal diseases are beginning to evolve and are delineated next.

CLINICAL IMPLICATIONS OF TISSUE REMODELING

Epithelial Changes in Relation to Fibrosis

The nonkeratinized squamous epithelial cells of the esophagus are important mediators of inflammation in EE. When in a Th2 milieu, the esophageal epithelium becomes an immunologically active tissue that expresses chemotactic factors for eosinophils,




Fig. 1. Eosinophil induction of esophageal remodeling and fibrosis in EE: relationships to endoscopic and histologic pathologies. Eosinophil activation during recruitment to the esophagus occurs in response to eotaxin-3, periostin, IL-5, and interactions with vascular endothelium, epithelium, and fibroblasts, leading to their expression of fibrogenic factors, such as TGF- β . Eosinophil-expressed TGF- β and granule proteins (MBP, EPO) induce epithelial basal zone hyperplasia, contributing to esophageal thickening and luminal narrowing. Eosinophil-derived TGF- β induces fibroblast activation, with transdifferentiation to myofibroblasts and consequent overproduction of ECM leading to subepithelial fibrosis, fixed narrowings and rings, strictures, and food impactions. Alternatively, TGF- β expressed by eosinophils or MBP-EPO damaged epithelium itself may induce epithelial to mesenchymal (myofibroblast) transition (EMT) contributing to subepithelial fibrosis. Eosinophil-expressed TGF- β may induce smooth muscle cell hypertrophy and hyperplasia leading to thickening of the esophageal muscularis propria, contributing to dysmotility, dysphagia, transient rings, and nonstricture food impactions. Eosinophil expression of vascular endothelial growth factor (VEGF) likely supports increased angiogenic responses of vascular endothelium with vascular cell adhesion molecule-1 (VCAM-1) activation by IL-13 and TNF- α , contributing to increased eosinophil trafficking, dilated intercellular spaces, esophageal thickening, furrowing, luminal narrowing, and nonstricture food impactions. (Adapted from Teitelbaum JE, Fox VL, Twarog FJ, et al. Eosinophilic esophagitis in children: immunopathological analysis and response to fluticasone propionate. *Gastroenterology* 2002;122:1221; Straumann A, Spichtin HP, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. *Gastroenterology* 2003;125(6):1665; Fox VL, Nurko S, Teitelbaum JE, et al. High-resolution EUS in children with eosinophilic "allergic" esophagitis. *Gastrointest Endosc* 2003;57:31, 33; Aceves SS, Newbury RO, Dohil R, et al. Esophageal remodeling in pediatric eosinophilic esophagitis. *J Allergy Clin Immunol* 2007;119:210; Wikimedia Commons; with permission. Endoscopic view of trachealization in eosinophilic esophagitis courtesy of A. F. Kagalwalla, MD, Chicago, IL.)

including eotaxin-3 and periostin.^{26,27} In addition, both an aeroallergen-driven murine model of EE and human biopsy specimens demonstrate the induction of mucin genes, such as muc-5, in the epithelium.²⁸

The Th2 cytokine, IL-13, is pivotal for airway remodeling. Studies in murine asthma models overexpressing airway epithelial IL-13 demonstrate robust tissue fibrosis and

airway mucous production.^{29,30} IL-13 also seems to be an important inflammatory mediator in EE with IL-13 mRNA levels induced 16-fold in epithelial biopsies from pediatric EE patients as compared with normal controls.³¹ Esophageal epithelial cells increase their production of eotaxin-3 in a signal transducer activation transcription-6 (STAT6)-dependent manner when cultured with IL-13, providing a potential positive feedback loop for eosinophil recruitment.^{16,31} The increased bulk of epithelial cells in EE patients, reflected in the histologic finding of basal zone hyperplasia and the endoscopic finding of epithelial mucosal thickening with luminal narrowing, may further enhance eosinophil recruitment and, hence, eosinophil-mediated esophageal remodeling and fibrosis (see **Fig. 1**). Although the eosinophil can be a significant cellular source of IL-13 in other disease states,³² the source of IL-13 in EE remains to be clearly identified.

Clinical Implications of Smooth Muscle Hyperplasia

Dysphagia, in part a reflection of esophageal dysmotility, is a cardinal and distinguishing clinical feature in both pediatric and adult EE.^{2,33–35} Pediatric studies⁵ have shown that EE patients complain of dysphagia at significantly higher rates than their normal, allergic, or gastroesophageal reflux disease counterparts.^{33,36,37} Whereas young children with EE have vomiting, heartburn, and poor growth, older children and adults often complain of persistent or recurrent dysphagia.^{8,38} In one adult series, 10% of patients who complained of solid food dysphagia met histologic criteria (defined as >20 eosinophils per hpf) for EE, and adults with EE are 2.6 times more likely to complain of dysphagia.³⁹

Studies of esophageal dysmotility in EE have occurred exclusively in adult patients. To date, 61 adult patients have had published motility studies.⁴⁰ Of these patients, 60% had abnormal motility, mainly categorized as spastic or hypercontractile.^{40,41} More recently, Hariprasad and colleagues⁴² have reported that the longitudinal muscle contractions in EE patients are abnormal, whereas circular muscle contractions are normal, leading to the dissociation of coordinated muscle contraction. The eosinophil, with granule products such as major basic protein-1 (MBP-1), which are known to alter smooth muscle contractility through inhibition of M2 muscarinic receptors,⁴³ may contribute to the motor dysfunction of the esophagus, and topical steroid therapy with resultant resolution of eosinophilia is associated with the resolution of esophageal dysmotility.⁴⁰

Muscular hypertrophy and hyperplasia may exacerbate the contractile abnormalities seen in EE. Although analyses of the smooth muscle in EE are limited to date, endoscopic ultrasound studies in pediatric EE patients have demonstrated thickening through the entire esophagus wall, including the mucosa and submucosa and the muscularis propria.¹⁰ Esophageal involvement in eosinophilic gastroenteritis is also reportedly associated with smooth muscle hypertrophy and infiltration of the muscularis propria with eosinophils.¹¹ Lastly, an EE model using inhaled *Aspergillus* demonstrates an increase in muscularis mucosa thickness.²⁸ Taken together, these data demonstrate that aeroallergen-driven EE can cause muscle hypertrophy and hyperplasia with eosinophilic inflammation. Resultant discordant hypercontractility, likely driven in part by eosinophil granule products, such as MBP-1, could explain the endoscopic finding of transient concentric rings and the clinical symptom of food impaction without strictures (see **Fig. 1**).

Pathogenic Mechanisms of Eosinophil-Smooth Muscle Interactions

Evidence for the pathophysiologic participation of eosinophils in smooth muscle hypertrophy and hyperplasia, contraction, and hyperreactivity to cholinergic agents comes from in vitro, animal model, and human studies of eosinophil-derived

transforming growth factor (TGF)- β and the eosinophil granule cationic proteins, particularly MBP-1, on airway bronchial smooth muscle in asthma. In chronic murine allergic asthma models, eosinophil-deficient mice show significant decreases in airway smooth muscle hyperplasia in association with decreased numbers of TGF- β -positive cells, primarily eosinophils, and myofibroblasts in the airways.^{24,44,45} Likewise, treatment of mild to moderate asthmatics with anti-IL-5 antibody (Mepolizumab) significantly decreases the numbers of TGF- β -positive cells, primarily eosinophils, in the airways, with concomitant decreases in airways remodeling in terms of the deposition of extracellular matrix proteins and numbers of myofibroblasts.^{19,25}

A connection between eosinophils and smooth muscle contractility was initially demonstrated by the ability of eosinophil granule cationic proteins, such as MBP-1, directly to induce airway smooth muscle contraction, bronchoconstriction, and airways hyperreactivity in rat,^{46,47} guinea pig,⁴⁸ and primate⁴⁹ asthma models. The mechanism by which eosinophils increase (airway) smooth muscle contractility and hyperresponsiveness to cholinergic stimulation was initially highlighted by studies demonstrating that MBP-1 is a potent antagonist of inhibitory M2 muscarinic receptors.⁵⁰ Studies in the guinea pig asthma model followed showing that parasympathetic neurons in the airways secrete eotaxin, which recruits eosinophils to the nerves, resulting in eosinophil secretion of MBP-1 and inhibition of M2 muscarinic receptors, leading to airways hyperreactivity.⁴³ Importantly, pretreatment of allergen-challenged guinea pigs with a neutralizing antibody to eosinophil MBP was shown to prevent airway hyperresponsiveness by protecting neuronal M2 muscarinic receptors.⁵¹ Hyperreactivity to histamine in this model was vagally mediated and dependent on MBP.⁵² Loss of M2 receptor function leads to increased acetylcholine release from cholinergic nerves, providing a mechanism for the vagally mediated airway hyperreactivity seen in this model.⁵³ Studies also showed that eosinophils localize to the airway nerves of sensitized animals after antigen challenge, and that inhibiting this localization with an antibody to IL-5⁵⁴ or the eosinophil adhesion molecule very late activation-4 (VLA-4),^{55,56} or with an eotaxin receptor (CCR3) antagonist,⁵⁷ prevents airway hyperreactivity subsequent to the loss of inhibitory M2 muscarinic receptor function. Although this mechanism remains to be confirmed in human asthma, loss of function of lung neuronal M2 muscarinic receptors may also occur, and neurons in human airways have been shown to secrete eotaxin⁵⁷ and to be infiltrated by eosinophils in fatal human asthma.⁵⁸ The rapid reappearance of both eosinophils and concentric rings (trachealization) in the esophagus of some EE patients within 2 to 3 days of reintroducing an offending food allergen into their diet is entirely consistent with eosinophil-mediated effects on smooth muscle or neurons through these types of mechanisms.⁵⁹ Whether eosinophils contribute to the discordant hypercontractility of esophageal smooth muscle directly in EE, or whether eosinophil-neuronal cell interactions contribute to the endoscopic finding of trachealization and clinical symptoms of food impaction in the absence of strictures remains to be determined.

Clinical Implications of Fibrosis

Fibrosis is defined histologically by increased collagen content of the subepithelial tissue. Although the exact collagen subtypes that are elevated in esophageal remodeling in EE remain to be elucidated, both adult and pediatric patients have increased subepithelial fibrosis.^{7,14,15} Fibrosis likely contributes to multiple clinical aspects of EE, including dysphagia symptoms, disease chronicity, and stricture formation.

Among pediatric EE patients with increased subepithelial fibrosis, 42% complain of dysphagia, often with concurrent food impaction.¹⁵ Pediatric EE patients with long-standing or stricture-associated disease have increased subepithelial collagen deposition as

compared with their normal or gastroesophageal reflux disease counterparts. It is likely that both TGF- β and the eosinophil play important roles in the mechanism of fibrosis in EE because pediatric EE patients have increased numbers of TGF- β_1 -producing cells and increased activation of the TGF- β signaling pathway as reflected by the increased numbers of cells expressing the nuclear phosphorylated Smad2/3 complex.¹⁴ The eosinophil is one cellular source of TGF- β in EE; patients and animals that lack eosinophils have diminished subepithelial fibrosis in response to aeroallergen challenge.^{14,28}

IL-5 is a master regulator of eosinophilopoiesis, trafficking, survival, and activation. Biopsies from both adult and pediatric EE patients demonstrate elevated IL-5 levels⁶⁰ and murine allergen-driven EE requires IL-5.²⁸ IL-5, together with the eotaxins, activates eosinophils to release their inflammatory products. IL-5-deficient EE mice lack esophageal subepithelial fibrosis,²⁸ and patients with both asthma and atopic dermatitis have decreased tissue remodeling of the airways and skin, respectively, when treated with a humanized monoclonal antibody that blocks IL-5.^{25,61} Adult EE patients treated with anti-IL-5 (Mepolizumab) have been reported to have decreased dysphagia and improvement in EE-associated strictures following therapy in a small open-label study,⁶² suggesting the role of eosinophils or IL-5 in the pathogenesis of human esophageal narrowing. In contrast, a recent placebo-controlled study of anti-IL-5 in adult EE patients showed approximately 55% decreases in esophageal eosinophils without improvements in clinical disease.⁶³ It is possible that, as suggested by studies with topical corticosteroids and food elimination or elemental diets, esophageal eosinophils may need to be reduced to near normal levels (ie, essentially no eosinophils) to reverse clinical symptoms, and anti-IL-5 alone may not be sufficient to induce significant clinical and pathologic remissions. Current clinical trials ongoing in EE should contribute to the understanding of the role of IL-5 and the eosinophil in esophageal remodeling and fibrosis.

Pathogenic Mechanisms of Eosinophil-Mediated Fibrosis

In addition to EE,^{10,64} eosinophils are considered a major effector cell of tissue fibrosis⁶⁵ in a variety of eosinophil-associated allergic diseases and hypereosinophilic syndromes including asthma,^{66,67} eosinophil myalgia syndrome,⁶⁸ eosinophilic endomyocardial fibrosis,²² idiopathic pulmonary fibrosis,⁶⁹ and scleroderma.⁶⁸ Eosinophils are implicated in fibrogenesis through these clinical disease associations; their elaboration of fibrogenic growth factors, such as TGF- β ,^{70,71} PDGF-BB,⁷² IL-1 β ,⁷³ and secretion of their granule cationic proteins, particularly MBP⁷⁴ and eosinophil peroxidase.⁷⁵ The association of degranulating eosinophils and deposition of their granule cationic proteins in tissues with pathologic fibrosis is a recurrent finding in a broad group of eosinophilic illnesses including EE.⁵ Eosinophils have been identified as the major TGF- β -producing cell in the lungs of asthmatics⁶⁷ and in the esophagus in pediatric EE.¹⁴

Both human and animal model studies provide compelling evidence for eosinophils as effectors of tissue remodeling and fibrosis. Reduction in bronchial eosinophils induced by treatment of asthmatics with anti-IL-5 antibody (Mepolizumab) decreases the expression of ECM proteins in the reticular basement membrane,²⁵ and anti-IL-5 similarly decreases both eosinophils and deposition of ECM proteins in allergen-induced late-phase skin reactions in atopic subjects.⁶¹ Direct evidence for eosinophil induction of remodeling and fibrosis comes from studies in eosinophil-deficient mice, demonstrating their essential role in the development of airway remodeling, including mucus (goblet) cell metaplasia, smooth muscle cell hyperplasia, and subepithelial fibrosis.^{20,44,45}

Multiple growth factors and cytokines expressed by eosinophils⁷⁶ are implicated in tissue remodeling and fibrosis. TGF- β , the most widely studied and potently

fibrogenic, regulates the expression of the profibrogenic cytokine IL-6; the myofibroblast marker α -smooth muscle actin (α -SMA); and other ECM proteins, such as the collagens. TGF- β expression is correlated with bronchial airway fibrosis and asthma severity,⁷⁷ and its overexpression in the lung in rodent animal models induces pulmonary fibrosis.⁷⁰

Eosinophil-fibroblast interactions have been implicated in the generation of subepithelial fibrosis and airway remodeling characteristic of human asthma in murine allergic asthma models.^{78,79} Mechanistic assessments of eosinophil-fibroblast interactions that may lead to fibrosis, however, are still limited. Rochester and colleagues⁷⁴ reported that eosinophil granule MBP synergizes with TGF- β or IL-1 β primed lung fibroblasts to induce significant increases in gene transcription and secretion of the IL-6 family of inflammatory and fibrogenic cytokines, including IL-6 and IL-11. TGF- β -induced fibroblast secretion of IL-6 is implicated in the overproduction of collagens, tissue inhibitor of metalloproteinases, and glycosaminoglycans in fibrogenesis.^{80,81} Eosinophil-lung fibroblast coculture in the presence of IL-5 induces fibroblasts to transdifferentiate into myofibroblasts with increased expression of α -SMA and ECM proteins.⁸² Eosinophils may indirectly impact fibroblast phenotype and fibrogenesis through activation of the epithelial-mesenchymal trophic unit⁸³ (eg, through secretion of MBP and eosinophil peroxidase) (see [Fig. 1](#)).⁷⁵ Alternatively, eosinophils may induce fibrogenesis through TGF- β induction of the epithelial to mesenchymal transition, as is shown to occur in the kidney⁸⁴ and lung.⁸⁵

Subepithelial fibrosis, a component of airway remodeling in asthma pathogenesis, is initiated by insults that include Th2-mediated allergic responses. Eosinophilic inflammation is thought to drive the differentiation of airway fibroblasts to myofibroblasts as characterized by the expression of myofibroblast-specific markers, such as α -SMA; the deposition of ECM proteins, such as collagens; fibronectin; and other ECM constituents, such as tenascin and lumican.^{25,83} Eosinophils recruited to the lung in asthma likely interact with fibroblasts beneath the reticular basement membrane, become activated to release their fibrogenic growth factors, such as TGF- β , driving fibroblasts to differentiate into myofibroblasts, which then deposit pathologic amounts of collagens and other ECM proteins contributing to airway subepithelial fibrosis.¹⁹ A report showing correlations between pulmonary expression of eotaxin-1, expression of eotaxin-1 receptor (CCR3), TGF- β_1 , and pulmonary fibrosis in a bleomycin mouse model supports this general mechanism.⁸⁶

Studies of eosinophil-mediated tissue remodeling and fibrosis in EE are still limited to date, principally because of the difficulties inherent in obtaining sufficient biopsies containing esophageal lamina propria below the stiffened hyperplastic epithelium. For this reason, evidence for progressive remodeling and fibrosis of the esophagus has been derived principally from endoscopic and radiologic features of the disease.⁷ The recent study by Aceves and colleagues,¹⁴ however, demonstrated that pediatric EE esophageal biopsies showed increased levels of subepithelial fibrosis and increased expression of TGF- β_1 by eosinophils and its signaling molecule phospho-SMAD2/3 compared with gastroesophageal reflux disease and normal controls. Beyond this report, the mechanisms regulating esophageal remodeling and fibrosis in chronic EE have not been systematically studied to define the changes in epithelial cell and fibroblast phenotype, the role of eosinophil-fibroblast interactions, or the contribution of epithelial to mesenchymal transition to this process.

Finally, recent genome-wide expression profiling studies of EE esophageal tissue that identified increased expression of eotaxin-3 as the principal mediator of eosinophil recruitment,²⁷ interestingly did not identify many genes known to participate in tissue remodeling and fibrosis, perhaps because the biopsy specimens analyzed were

sufficiently superficial to include mainly hyperplastic epithelium and not subepithelial fibrotic tissue. One of the identified genes, however, periostin, expressed predominantly in collagen-rich fibrous connective tissues subject to mechanical stresses and in wound healing, has been reported to participate in the development of subepithelial fibrosis in bronchial asthma downstream of the IL-4 and IL-13 signals.⁸⁷ Primary esophageal fibroblasts have recently been shown to release periostin when cultured with IL-13 and TGF- β .²⁶ Periostin, found mainly in the vascular papillae (projections of subepithelial lamina propria into the epithelium) in the esophagus, could contribute to eosinophil trafficking by increasing eosinophil adhesion to fibronectin.²⁶ Eosinophil-derived TGF- β , through induction of fibroblast periostin expression, might provide an amplification loop for eosinophilic inflammation and its consequent induction of the remodeling and fibrosis characteristic of EE.

Clinical Implications of Angiogenesis

Angiogenesis, the formation of new blood vessels, has a number of implications in inflammatory diseases, such as EE. Increased vasculature increases the density of conduits for inflammatory cell trafficking, propagating inflammation. In addition, ILs and histamine can modulate vascular permeability and lead to enhanced tissue edema. One of the histologic features of EE is dilated intercellular spaces,⁸⁸ which may be a reflection of increased tissue edema and, ultimately, increased mucosal and submucosal thickness when compared with control patients.^{89,90} Linear furrowing, caused by a thickened esophagus folding on itself, could be an endoscopic finding related to esophageal edema. Ultimately, an edematous esophagus decreases luminal size and predisposes to clinical complications, such as food impaction.

Pediatric EE patients have an increased vascular density as compared with their age-matched counterparts with either a normal esophagus or esophagitis associated with gastroesophageal reflux disease.¹⁴ Blood vessels from EE patients also demonstrate an activated endothelial phenotype with increased expression of vascular cell adhesion molecule-1 (VCAM-1).¹⁴ VCAM-1 interactions with the cognate ligand VLA-4 molecule allows leukocytes, particularly eosinophils, selectively to traffic to Th2 activated tissues. Interestingly, IL-13 and tumor necrosis factor- α can induce vascular endothelial VCAM-1 expression, and both are present at elevated levels in the esophageal mucosa in patients EE.^{17,31}

Recent EE animal model studies demonstrate that IL-13 also increases vessel density in EE in a manner dependent on IL-13 interaction with IL-13R α 2.⁹¹ Mice with increased expression of airway Clara cell CC-10-driven IL-13 have increased esophageal vascular density and increased esophageal circumference,⁹¹ consistent with the linear furrowing and luminal narrowing seen in the human disease; this IL-13 effect is dependent on an intact IL-13R α .⁹¹ Because pediatric EE patients demonstrate an elevated expression of IL-13 mRNA,³¹ IL-13 is also implicated in the generation of new blood vessels in the human disease. Animal models have also shown that the induction of EE by IL-13 is dependent on both IL-5 and STAT6,^{16,31} and therapy with either IL-5 or IL-13 blocking agents^{62,92} may remediate not only esophageal fibrosis, but also the increased angiogenesis associated with EE.¹⁴

PATHOGENIC MECHANISMS OF EOSINOPHIL-INDUCED ANGIOGENESIS

Eosinophils express a number of angiogenic factors, not the least of which is vascular endothelial growth factor (VEGF),⁹³ and they are implicated in the increased angiogenesis seen in many eosinophil-associated allergic inflammatory diseases, such as asthma.^{94–96} The expression of VEGF, basic fibroblast growth factor, angiogenin,

and the VEGF receptors (flt-1 and flk-1) is increased in asthmatic airways, and the numbers of cells including eosinophils expressing these factors and receptors is correlated with measurements of increased lung vascularity.^{97,98} Increased expression of VEGF has been demonstrated in the induced sputum of asthmatic children, supporting the concept that it participates in the pathophysiology of augmented angiogenesis seen in bronchial asthma.⁹⁹

Eosinophils, through expression of VEGF, have been shown experimentally by Puxeddu and colleagues⁹⁶ to induce new vessel formation in chick embryo models. Blood eosinophil extracts were found to induce rat aortic endothelial cell proliferation in vitro, rat aorta sprouting ex vivo, and angiogenesis in the chick embryo chorioallantoic membrane in vivo.¹⁰⁰ These proangiogenic effects were mediated principally by eosinophil-expressed VEGF, because they could significantly be inhibited by neutralizing antibodies to VEGF.¹⁰⁰ Intact eosinophils were found to induce VEGF mRNA expression and increased VEGF receptor density expression on endothelial cells, to enhance endothelial cell proliferation, and to augment angiogenic responses in aorta rings and chorioallantoic membranes.¹⁰⁰ Eosinophils are capable of inducing angiogenesis, in part by their secretion of preformed VEGF.⁹⁶ Whether eosinophils, through their expression of angiogenic factors, such as VEGF (see **Fig. 1**), contribute to increased vascularization and activated VCAM-1–positive vascular endothelium in the esophagus, as shown in children with EE,¹⁴ remains to be determined.

THERAPEUTICS AND TISSUE REMODELING

Currently, there are no large clinical trials that demonstrate the efficacy of EE therapies on reducing tissue remodeling and fibrosis. One case report demonstrates that inhaled budesonide in a patient with stricture-associated EE and concurrent asthma was associated with decreased subepithelial fibrosis following 2 months of therapy.¹⁰¹ Current observations demonstrate that a subset of children with EE have reversal of deep tissue remodeling following topical esophageal corticosteroid therapy (Aceves and Broide, unpublished data, 2008). Successful EE therapy with swallowed fluticasone results in the normalization of an EE-specific transcriptome, including IL-13.³¹ As such, topical corticosteroids could diminish esophageal remodeling by their effects on the esophageal levels of ILs, such as IL-13. Anti-IL-5 therapy has also been reported to result in the improvement of EE-associated strictures and esophageal narrowing and improvement of basal zone hyperplasia and eosinophilic inflammation in an open-label trial in a small number of patients.⁶² In contrast, a second placebo-controlled study in adults with severe EE concluded that anti-IL-5 therapy, although effective in reducing the numbers of esophageal eosinophils on average by approximately 55% (but not less than 10 eosinophils per hpf), showed little efficacy in reducing patients' clinical symptom scores.⁶³ Whether this is sufficient to result in histologic remission of the remodeling and fibrosis of the subepithelial tissue in EE remains to be determined. Of note, this finding is reminiscent of the first studies of anti-IL-5 therapy in asthmatic subjects, in which reductions of pulmonary tissue eosinophils by approximately 55% did not significantly impact pulmonary function or airway hyperreactivity,^{102,103} but did significantly reduce the deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.²⁵ These results suggest that an additional therapy (eg, one targeting eosinophil recruitment through antagonism of eotaxin-3 or its receptor on eosinophils [CCR3]) may need to be combined with anti-IL-5 to achieve a therapeutic reduction in eosinophils with complete endoscopic and histologic remission of esophageal remodeling in EE.

SUMMARY

The central role of the eosinophil in esophageal remodeling and subepithelial fibrosis, and the relationships of this remodeling to the clinical signs, symptoms, and pathogenesis of EE, are now beginning to be defined at the cellular and molecular levels, but clearly warrant further study. The natural history of EE, the time frame from disease onset to the development of epithelial hyperplasia, thickening of the muscularis propria and esophageal wall, and subepithelial deposition of collagens and other ECM constituents that contribute to esophageal remodeling and fibrosis in EE, however, are still not well defined. Also unclear are the relationships of esophageal remodeling to disease severity and duration, and to what extent esophageal remodeling and fibrosis are reversible with treatments that significantly reduce tissue eosinophils in the esophagus. Better understanding of the mechanisms by which eosinophils promote tissue remodeling and fibrogenesis in the esophagus should contribute to the development of novel therapeutic approaches for blocking eosinophil recruitment to the esophagus or reversing the debilitating consequences of esophageal remodeling in EE, and the tissue remodeling and fibrosis seen in many other eosinophil-associated allergic diseases and hypereosinophilic syndromes.

REFERENCES

1. Chehade M, Sampson HA. Epidemiology and etiology of eosinophilic esophagitis. *Gastrointest Endosc Clin N Am* 2008;18:33–44, viii.
2. Potter JW, Saeian K, Staff D, et al. Eosinophilic esophagitis in adults: an emerging problem with unique esophageal features. *Gastrointest Endosc* 2004;59:355–61.
3. Straumann A, Simon HU. Eosinophilic esophagitis: escalating epidemiology? *J Allergy Clin Immunol* 2005;115:418–9.
4. Vanderheyden AD, Petras RE, DeYoung BR, et al. Emerging eosinophilic (allergic) esophagitis: increased incidence or increased recognition? *Arch Pathol Lab Med* 2007;131:777–9.
5. Liacouras CA, Bonis P, Putnam PE, et al. Summary of the first international gastrointestinal research symposium. *J Pediatr Gastroenterol Nutr* 2007;45:370–91.
6. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. *N Engl J Med* 2004;351:940–1.
7. Straumann A, Spichtin HP, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. *Gastroenterology* 2003;125:1660–9.
8. Straumann A. The natural history and complications of eosinophilic esophagitis. *Gastrointest Endosc Clin N Am* 2008;18:99–118, ix.
9. Assa'ad AH, Putnam PE, Collins MH, et al. Pediatric patients with eosinophilic esophagitis: an 8-year follow-up. *J Allergy Clin Immunol* 2007;119:731–8.
10. Fox VL, Nurko S, Teitelbaum JE, et al. High-resolution EUS in children with eosinophilic allergic esophagitis. *Gastrointest Endosc* 2003;57:30–6.
11. Stevoff C, Rao S, Parsons W, et al. EUS and histopathologic correlates in eosinophilic esophagitis. *Gastrointest Endosc* 2001;54:373–7.
12. Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. *Gastroenterology* 2007;133:1342–63.
13. Noel RJ, Putnam PE, Collins MH, et al. Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. *Clin Gastroenterol Hepatol* 2004;2:568–75.

14. Aceves SS, Newbury RO, Dohil R, et al. Esophageal remodeling in pediatric eosinophilic esophagitis. *J Allergy Clin Immunol* 2007;119:206–12.
15. Chehade M, Sampson HA, Morotti RA, et al. Esophageal subepithelial fibrosis in children with eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr* 2007;45:319–28.
16. Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. *Gastroenterology* 2003;125:1419–27.
17. Straumann A, Kristl J, Conus S, et al. Cytokine expression in healthy and inflamed mucosa: probing the role of eosinophils in the digestive tract. *Inflamm Bowel Dis* 2005;11:720–6.
18. Jacobsen EA, Ochkur SI, Lee NA, et al. Eosinophils and asthma. *Curr Allergy Asthma Rep* 2007;7:18–26.
19. Kay AB, Phipps S, Robinson DS. A role for eosinophils in airway remodelling in asthma. *Trends Immunol* 2004;25:477–82.
20. Lee JJ, Dimina D, Macias MP, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. *Science* 2004;305:1773–6.
21. Tai PC, Ackerman SJ, Spry CJ, et al. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. *Lancet* 1987;1:643–7.
22. Spry CJ. The pathogenesis of endomyocardial fibrosis: the role of the eosinophil. *Springer Semin Immunopathol* 1989;11:471–7.
23. Jacobsen EA, Ochkur SI, Pero RS, et al. Allergic pulmonary inflammation in mice is dependent on eosinophil-induced recruitment of effector T cells. *J Exp Med* 2008;205:699–710.
24. Ochkur SI, Jacobsen EA, Protheroe CA, et al. Coexpression of IL-5 and eotaxin-2 in mice creates an eosinophil-dependent model of respiratory inflammation with characteristics of severe asthma. *J Immunol* 2007;178:7879–89.
25. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. *J Clin Invest* 2003;112:1029–36.
26. Blanchard C, Mingler MK, McBride M, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. *Mucosal Immunol* 2008;1:289–96.
27. Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. *J Clin Invest* 2006;116:536–47.
28. Mishra A, Wang M, Pemmaraju VR, et al. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. *Gastroenterology* 2008;134:204–14.
29. Fulkerson PC, Fischetti CA, Rothenberg ME. Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling. *Am J Pathol* 2006;169:2117–26.
30. Zhu Z, Homer RJ, Wang Z, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. *J Clin Invest* 1999;103:779–88.
31. Blanchard C, Mingler MK, Vicario M, et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. *J Allergy Clin Immunol* 2007;120:1292–300.
32. Schmid-Grendelmeier P, Altnauer F, Fischer B, et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. *J Immunol* 2002;169:1021–7.

33. Aceves SS, Newbury RO, Dohil R, et al. Distinguishing eosinophilic esophagitis in pediatric patients: clinical, endoscopic, and histologic features of an emerging disorder. *J Clin Gastroenterol* 2007;41:252–6.
34. Kapel RC, Miller JK, Torres C, et al. Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups. *Gastroenterology* 2008;134:1316–21.
35. Parfitt JR, Gregor JC, Suskin NG, et al. Eosinophilic esophagitis in adults: distinguishing features from gastroesophageal reflux disease: a study of 41 patients. *Mod Pathol* 2006;19:90–6.
36. Aceves SS, Arie B, Dohil M, et al. Prospective analysis of an abdominal symptom scoring system tool's efficacy in the clinical distinction of pediatric eosinophilic esophagitis from gastroesophageal reflux disease. *J Allergy Clin Immunol* 2008;121:S70.
37. Aceves SS, Furuta GT, Spechler SJ. Integrated approach to treatment of children and adults with eosinophilic esophagitis. *Gastrointest Endosc Clin N Am* 2008;18:195–217, xi.
38. Noel RJ, Tipnis NA. Eosinophilic esophagitis: a mimic of GERD. *Int J Pediatr Otorhinolaryngol* 2006;70:1147–53.
39. Prasad GA, Talley NJ, Romero Y, et al. Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. *Am J Gastroenterol* 2007;102:2627–32.
40. Lucendo AJ, Pascual-Turrión JM, Navarro M, et al. Endoscopic, bioptic, and manometric findings in eosinophilic esophagitis before and after steroid therapy: a case series. *Endoscopy* 2007;39:765–71.
41. Remedios M, Campbell C, Jones DM, et al. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. *Gastrointest Endosc* 2006;63:3–12.
42. Korsapati HR, Dohil R, Quinn AM, et al. Normal circular muscle but dysfunctional longitudinal muscle in eosinophilic esophagitis. *Gastroenterology* 2008;134:A-59.
43. Jacoby DB, Costello RM, Fryer AD. Eosinophil recruitment to the airway nerves. *J Allergy Clin Immunol* 2001;107:211–8.
44. Cho JY, Miller M, Baek KJ, et al. Inhibition of airway remodeling in IL-5-deficient mice. *J Clin Invest* 2004;113:551–60.
45. Humbles AA, Lloyd CM, McMillan SJ, et al. A critical role for eosinophils in allergic airways remodeling. *Science* 2004;305:1776–9.
46. Coyle AJ, Ackerman SJ, Burch R, et al. Human eosinophil-granule major basic protein and synthetic polycations induce airway hyperresponsiveness in vivo dependent on bradykinin generation. *J Clin Invest* 1995;95:1735–40.
47. Coyle AJ, Ackerman SJ, Irvin CG. Cationic proteins induce airway hyperresponsiveness dependent on charge interactions. *Am Rev Respir Dis* 1993;147:896–900.
48. Desai SN, Van G, Robson J, et al. Human eosinophil major basic protein augments bronchoconstriction induced by intravenous agonists in guinea pigs. *Agents Actions* 1993;39(Spec No):C132–5.
49. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. *J Clin Invest* 1991;87:1470–3.
50. Jacoby DB, Gleich GJ, Fryer AD. Human eosinophil major basic protein is an endogenous allosteric antagonist at the inhibitory muscarinic M2 receptor. *J Clin Invest* 1993;91:1314–8.
51. Evans CM, Fryer AD, Jacoby DB, et al. Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2

- muscarinic receptors in antigen-challenged guinea pigs. *J Clin Invest* 1997;100:2254–62.
52. Costello RW, Evans CM, Yost BL, et al. Antigen-induced hyperreactivity to histamine: role of the vagus nerves and eosinophils. *Am J Physiol* 1999;276:L709–14.
 53. Costello RW, Jacoby DB, Gleich GJ, et al. Eosinophils and airway nerves in asthma. *Histol Histopathol* 2000;15:861–8.
 54. Elbon CL, Jacoby DB, Fryer AD. Pretreatment with an antibody to interleukin-5 prevents loss of pulmonary M2 muscarinic receptor function in antigen-challenged guinea pigs. *Am J Respir Cell Mol Biol* 1995;12:320–8.
 55. Fryer AD, Costello RW, Yost BL, et al. Antibody to VLA-4, but not to L-selectin, protects neuronal M2 muscarinic receptors in antigen-challenged guinea pig airways. *J Clin Invest* 1997;99:2036–44.
 56. Yost BL, Gleich GJ, Jacoby DB, et al. The changing role of eosinophils in long-term hyperreactivity following a single ozone exposure. *Am J Physiol Lung Cell Mol Physiol* 2005;289:L627–35.
 57. Fryer AD, Stein LH, Nie Z, et al. Neuronal eotaxin and the effects of CCR3 antagonist on airway hyperreactivity and M2 receptor dysfunction. *J Clin Invest* 2006;116:228–36.
 58. Costello RW, Schofield BH, Kephart GM, et al. Localization of eosinophils to airway nerves and effect on neuronal M2 muscarinic receptor function. *Am J Physiol* 1997;273:L93–103.
 59. Gonsalves N, Yang G-Y, Doerfler B, et al. A prospective clinical trial of six food elimination diet and reintroduction of causative agents in adults with eosinophilic esophagitis. *Gastroenterology* 2008;134:A104.
 60. Straumann A, Bauer M, Fischer B, et al. Idiopathic eosinophilic esophagitis is associated with a T(H)2-type allergic inflammatory response. *J Allergy Clin Immunol* 2001;108:954–61.
 61. Phipps S, Flood-Page P, Menzies-Gow A, et al. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. *J Invest Dermatol* 2004;122:1406–12.
 62. Stein ML, Collins MH, Villanueva JM, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. *J Allergy Clin Immunol* 2006;118:1312–9.
 63. Straumann A, Conus S, Kita H, et al. Mepolizumab, a humanized antibody to IL-5, for severe eosinophilic esophagitis in adults: a randomized, placebo-controlled double-blind trial. *J Allergy Clin Immunol* 2008;121:S44.
 64. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). *J Allergy Clin Immunol* 2004;113:11–28 [quiz 29].
 65. Gharaee-Kermani M, Phan SH. The role of eosinophils in pulmonary fibrosis. *Int J Mol Med* 1998;1:43–53.
 66. Kay AB. The role of eosinophils in the pathogenesis of asthma. *Trends Mol Med* 2005;11:148–52.
 67. Minshall EM, Leung DY, Martin RJ, et al. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. *Am J Respir Cell Mol Biol* 1997;17:326–33.
 68. Varga J, Kahari VM. Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. *Curr Opin Rheumatol* 1997;9:562–70.
 69. Gharaee-Kermani M, Phan SH. Molecular mechanisms of and possible treatment strategies for idiopathic pulmonary fibrosis. *Curr Pharm Des* 2005;11:3943–71.
 70. Gaudie J, Sime PJ, Xing Z, et al. Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis. *Curr Top Pathol* 1999;93:35–45.

71. Ohno I, Nitta Y, Yamauchi K, et al. Transforming growth factor beta 1 (TGF-beta 1) gene expression by eosinophils in asthmatic airway inflammation. *Am J Respir Cell Mol Biol* 1996;15:404–9.
72. Ohno I, Nitta Y, Yamauchi K, et al. Eosinophils as a potential source of platelet-derived growth factor B-chain (PDGF-B) in nasal polyposis and bronchial asthma. *Am J Respir Cell Mol Biol* 1995;13:639–47.
73. Gomes I, Mathur SK, Espenshade BM, et al. Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis. *J Allergy Clin Immunol* 2005;116:796–804.
74. Rochester CL, Ackerman SJ, Zheng T, et al. Eosinophil-fibroblast interactions: granule major basic protein interacts with IL-1 and transforming growth factor-beta in the stimulation of lung fibroblast IL-6-type cytokine production. *J Immunol* 1996;156:4449–56.
75. Pegorier S, Wagner LA, Gleich GJ, et al. Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells. *J Immunol* 2006;177:4861–9.
76. Lacy P, Moqbel R. Eosinophil cytokines. *Chem Immunol* 2000;76:134–55.
77. Minshall EM, Cameron L, Lavigne F, et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. *Am J Respir Cell Mol Biol* 1997;17:683–90.
78. Hoshino M, Nakamura Y, Sim J, et al. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. *J Allergy Clin Immunol* 1998;102:783–8.
79. Hoshino M, Nakamura Y, Sim JJ. Expression of growth factors and remodelling of the airway wall in bronchial asthma. *Thorax* 1998;53:21–7.
80. Eickelberg O, Pansky A, Mussmann R, et al. Transforming growth factor-beta1 induces interleukin-6 expression via activating protein-1 consisting of JunD homodimers in primary human lung fibroblasts. *J Biol Chem* 1999;274:12933–8.
81. Varga J, Jimenez SA. Modulation of collagen gene expression: its relation to fibrosis in systemic sclerosis and other disorders. *Ann Intern Med*. 1995;122:60–2.
82. Phipps S, Ying S, Wangoo A, et al. The relationship between allergen-induced tissue eosinophilia and markers of repair and remodeling in human atopic skin. *J Immunol* 2002;169:4604–12.
83. Phipps S, Benyahia F, Ou TT, et al. Acute allergen-induced airway remodeling in atopic asthma. *Am J Respir Cell Mol Biol* 2004;31:626–32.
84. Zeisberg M, Kalluri R. Fibroblasts emerge via epithelial-mesenchymal transition in chronic kidney fibrosis. *Front Biosci* 2008;13:6991–8.
85. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. *Proc Natl Acad Sci U S A* 2006;103:13180–5.
86. Haux F, Gharaee-Kermani M, Liu T, et al. Role of Eotaxin-1 (CCL11) and CC chemokine receptor 3 (CCR3) in bleomycin-induced lung injury and fibrosis. *Am J Pathol* 2005;167:1485–96.
87. Takayama G, Arima K, Kanaji T, et al. Periostin: a novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. *J Allergy Clin Immunol* 2006;118:98–104.
88. Ravelli AM, Villanacci V, Ruzzenenti N, et al. Dilated intercellular spaces: a major morphological feature of esophagitis. *J Pediatr Gastroenterol Nutr* 2006;42:510–5.
89. Fox VL. Eosinophilic esophagitis: endoscopic findings. *Gastrointest Endosc Clin N Am* 2008;18:45–57, viii.

90. Mueller S, Aigner T, Neureiter D, et al. Eosinophil infiltration and degranulation in oesophageal mucosa from adult patients with eosinophilic oesophagitis: a retrospective and comparative study on pathological biopsy. *J Clin Pathol* 2006;59:1175–80.
91. Zuo L, Mingler M, Blanchard C, et al. IL-13 transgene induced experimental eosinophilic esophagitis is associated with increased esophageal circumference and extensive angiogenesis. *J Allergy Clin Immunol* 2008;121:S72.
92. Blanchard C, Mishra A, Saito-Akei H, et al. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). *Clin Exp Allergy* 2005;35:1096–103.
93. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. *Am J Respir Cell Mol Biol* 1997;17:70–7.
94. Aceves SS, Broide DH. Airway fibrosis and angiogenesis due to eosinophil trafficking in chronic asthma. *Curr Mol Med* 2008;8:350–8.
95. Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. *J Allergy Clin Immunol* 2008;121:560–70 [quiz 571–2].
96. Puxeddu I, Ribatti D, Crivellato E, et al. Mast cells and eosinophils: a novel link between inflammation and angiogenesis in allergic diseases. *J Allergy Clin Immunol* 2005;116:531–6.
97. Hoshino M, Nakamura Y, Hamid QA. Gene expression of vascular endothelial growth factor and its receptors and angiogenesis in bronchial asthma. *J Allergy Clin Immunol* 2001;107:1034–8.
98. Hoshino M, Takahashi M, Aoike N. Expression of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin immunoreactivity in asthmatic airways and its relationship to angiogenesis. *J Allergy Clin Immunol* 2001;107:295–301.
99. Hossny E, El-Awady H, Bakr S, et al. Vascular endothelial growth factor overexpression in induced sputum of children with bronchial asthma. *Pediatr Allergy Immunol* 2008, in press.
100. Puxeddu I, Alian A, Piliponsky AM, et al. Human peripheral blood eosinophils induce angiogenesis. *Int J Biochem Cell Biol* 2005;37:628–36.
101. Maples KM, Henderson SC, Graham M, et al. Treatment of eosinophilic esophagitis with inhaled budesonide in a 7-year-old boy with concomitant persistent asthma: resolution of esophageal submucosal fibrosis and eosinophilic infiltration. *Ann Allergy Asthma Immunol* 2007;99:572–4.
102. Flood-Page PT, Menzies-Gow AN, Kay AB, et al. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. *Am J Respir Crit Care Med* 2003;167:199–204.
103. Leckie MJ, ten Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. *Lancet* 2000;356:2144–8.